CN1478551A - Medicine used in medical breath diagnosis - Google Patents
Medicine used in medical breath diagnosis Download PDFInfo
- Publication number
- CN1478551A CN1478551A CNA021346232A CN02134623A CN1478551A CN 1478551 A CN1478551 A CN 1478551A CN A021346232 A CNA021346232 A CN A021346232A CN 02134623 A CN02134623 A CN 02134623A CN 1478551 A CN1478551 A CN 1478551A
- Authority
- CN
- China
- Prior art keywords
- medicine
- chemical compound
- acid
- abundance
- container
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A medicine for medical expiration diagnosis includes 13C marker compound, and features that the richness of 13C at one marked position is 50-95%. As it is prepared from the compound whose richness of 13C is lower, it has short preparing period and low cost.
Description
Technical field
The present invention relates to medical diagnostic techniqu, be specifically related to be used for the medicine of medical breath diagnosis.
Background technology
Utilize the stable isotopic tracer technology, realize medical diagnosis, accepted by numerous doctors and patient day by day by breath test.Prior art adopts abundance 99%
13C isotopic labeling medicine, its manufacturing cycle is long, and the expense height makes that the cost of this expiration experiment is too high, is difficult to be popularized.
Summary of the invention
The technical problem to be solved in the present invention is, the novel medicine that is used for medical breath diagnosis is provided, and has short production cycle and lower preparation expense, and, can guarantee the accuracy of medical breath diagnosis.
The above-mentioned technical problem of the present invention is to solve like this, construct a kind of medicine that is used for medical breath diagnosis, comprises making certain dosage form
13The C labelled compound is characterized in that, at least one mark position of described chemical compound
13The C abundance is 50-95%.
According to the medicine that is used for medical breath diagnosis provided by the invention, described chemical compound and specific markers position can be a kind of in following:
13C-caffeine (3-methyl-
13C),
13C-aminophenazone (n, n-dimethyl-
13C),
13C-Mei Shaxiding (methoxy-
13C),
13C-phenacetin (ethoxy-1-
13C),
13The C-triolein (1,1,1-
13C),
13The C-tricaprylin (1,1,1-
13C),
13The C-xylose or
13C-pentose (1-
13C).
According to the medicine that is used for medical breath diagnosis provided by the invention, described chemical compound can be a kind of in the following chemical compound:
13C-carbamide,
13C-erythromycin,
13The C-phenylalanine,
13The C-corn starch,
13The C-Semen Maydis oil,
13C-triglyceride (blended),
13The C-tripalmitin,
13C-sucrose,
13The C-lactose,
13The C-acetas,
13C-acetic acid,
13C-is sad,
13The C-caprylate,
13C-carbonic acid,
13The C-glycine,
13C-glycerol cholic acid,
13C-ketone group isocaproic acid,
13C-ethanol,
13The C-valproic acid,
13The C-fatty acid.
According to the medicine that is used for medical breath diagnosis provided by the invention, prepare the raw material of described chemical compound
13C be directly by low temperature distillation, chromatographic isolation, electromagnetic separation, isotope diffusion, biological concentration or and the mode of combination directly obtain.
According to the medicine that is used for medical breath diagnosis provided by the invention, described certain dosage form is capsule or tablet, also comprises the container that is used to place described capsule or tablet, and described container can be box, bottle, sack.
According to the medicine that is used for medical breath diagnosis provided by the invention, described certain dosage form is a solution, also comprises the container that is used to place described solution, and described container can be a bottle.
According to the medicine that is used for medical breath diagnosis provided by the invention, in described chemical compound specific markers position
13The C abundance is 60-90%.
According to the medicine that is used for medical breath diagnosis provided by the invention, in described chemical compound specific markers position
13The C abundance is 60-85%.
Enforcement owing to adopt low abundance, therefore can be shortened manufacturing cycle according to the medicine that is used for medical breath diagnosis provided by the invention greatly, reduces production costs, and makes the popularization and application of medical breath diagnosis become possibility.
The specific embodiment
Embodiment 1:
The employing chemical compound is
13C-carbamide, abundance are 58%, carry out breath test simultaneously with traditional 99% abundance product, have identical diagnostic accuracy, and this chemical compound is to adopt
13The C abundance is that 58% carbon monoxide is obtained as raw material is synthetic, and this raw material is to obtain in the middle of traditional low temperature distillation preparation process, also can obtain by electromagnetic separation, chromatographic isolation combination technique.Like this, its preparation cost will be significantly less than by with abundance 99%
13C-carbamide dilutes and obtains 58%
13The required cost of equivalent medicine of C abundance because prepare 99% and the cost of above abundance chemical compound be very expensive.Further, said medicine can be made into capsule, in batches capsulation in sack, the person that needs the breath test, as long as take out wherein capsule obey into, every the certain hour detection of exhaling, carry out medical diagnosis on disease according to detected result.
Embodiment 2:
The employing chemical compound is
13C-aminophenazone, abundance are 95%, and the process check has concordance with the diagnostic result of traditional 99% abundance product, because the raw material that this medicine adopts is an abundance 95%
13C-chemical compound (this chemical compound can be carbon monoxide, carbon dioxide, brium carbonate etc.), utilize electromagnetic separation and chromatographic isolation combination technique to obtain, also can in the middle of traditional excessively low temperature distillation preparation process, it be obtained, so expense is significantly less than by preparing
13C abundance 99%
13The C-aminophenazone dilutes and obtains abundance 95%
13The needed cost of C-aminophenazone.Said medicine is made into tablet, and in batches tablet medicine is packaged in the bottle again, during breath test, therefrom takes out under several clothes and gets final product.
Embodiment 3:
Successively adopt chemical compound and molecular formula thereof as follows, in the round bracket be
13The ad-hoc location of C labelling: 1,
13C-carbamide [
13C-Urea] 3,
13C-aminophenazone [Aminopyrine (n, n-dimethyl-
13C)] 4,
13C-Mei Shaxiding [Methacetin (methoxy-
13C)] 5,
13C-phenacetin [Phenacetin (ethoxy-1-
13C)] 6,
13C-erythromycin [
13C-Erythromycin] 7,
13The C-phenylalanine [
13C-Phenylalanine] 8,
13The C-triolein [Triolein (1,1,1-
13C)] 9,
13The C-tricaprylin [Trioctanoin (1,1,1-
13C)] 10,
13The C-corn starch [
13C-Maize Starch] 11,
13The C-Semen Maydis oil [
13C-Maize Oil] 12,
13C-triglyceride (blended) [
13C-Triglycerides (mixed)] 13,
13The C-tripalmitin [
13C-Tripalmitin] 14,
13The C-xylose or
13C-pentose [D-Xylose (1-
13C)] 15,
13C-sucrose [
13C-Sucrose] 16,
13The C-lactose [
13C-Lactose] 17,
13The C-acetas [
13C-Acetate] 18,
13C-acetic acid [
13C-Acetic Acid] 19,
13C-sad [
13C-Octanoate] 20,
13The C-caprylate [
13C-Octanoic Acid] 21,
13C-carbonic acid [
13C-Hydrogen Carbonate] 22,
13The C-glycine [
13C-Glycine] 23,
13C-glycerol cholic acid [
13C-Glycocholic Acid] 24,
13C-ketone group isocaproic acid [
13C-Ketoisocaproic Acid] 25,
13C-ethanol [
13C-Ethanol] 26,
13The C-valproic acid [
13C-Valproic Acid] 27,
13The C-fatty acid [
13C-Fatty Acid] 28,
13C-caffeine [Caffeine (3-methyl-
13C)] 29,
13C-aminophenazone [Aminopyrine (n, n-dimethyl-
13C)] 30,
13C-Mei Shaxiding [Methacetin (methoxy-
13C)] 31,
13C-phenacetin [Phenacetin (ethoxy-1-
13C)] 32,
13The C-triolein [Triolein (1,1,1-
13C)] 33,
13The C-tricaprylin [Trioctanoin (1,1,1-
13C)] 34,
13The C-corn starch [
13C-Maize Stareh] 35,
13The C-tripalmitin [
13C-Tripalmitin] 36,
13The C-xylose or
13C-pentose [D-Xylose (1-
13C)]
Experiment shows which kind of dosage form no matter medicine of the present invention adopt, because its synthetic raw material that adopts, promptly
13The C abundance is the carbon compound of 50-95%, all directly directly obtains by the mode of low temperature distillation, chromatographic isolation and electromagnetic separation or isotope diffusion, biological concentration and combination thereof, therefore, can reduce greatly
13The preparation cost of C labelling breath test medicine, thus make stable isotope breath diagnosis technology obtain higher generalization and universal.
Claims (8)
1. the cold labeling medicine that is used for medical breath diagnosis comprises and makes certain dosage form
13The C labelled compound is characterized in that, at least one mark position of described chemical compound
13The C abundance is 50-95%.
2. according to the described medicine of claim 1, it is characterized in that described chemical compound can be a kind of in the following chemical compound,
13C-carbamide,
13C-erythromycin,
13The C-phenylalanine,
13The C-corn starch,
13The C-Semen Maydis oil,
13C-triglyceride (blended),
13The C-tripalmitin,
13C-sucrose,
13The C-lactose,
13The C-acetas,
13C-acetic acid,
13C-is sad,
13The C-caprylate,
13C-carbonic acid,
13The C-glycine,
13C-glycerol cholic acid,
13C-ketone group isocaproic acid,
13C-ethanol,
13The C-valproic acid,
13The C-fatty acid.
3. according to the described medicine of claim 1, it is characterized in that described chemical compound and mark position thereof can be a kind of in following:
13C-caffeine (3-methyl-
13C),
13C-aminophenazone (n, n-dimethyl-
13C),
13C-Mei Shaxiding (methoxy-
13C),
13C-phenacetin (ethoxy-1-
13C),
13The C-triolein (1,1,1-
13C),
13The C-tricaprylin (1,1,1-
13C),
13The C-xylose or
13C-pentose (1-
13C).
4. according to any one described medicine of claim 1-3, it is characterized in that, prepare the raw material of described chemical compound
13C directly directly obtains by the mode of low temperature distillation, chromatographic isolation, electromagnetic separation, isotope diffusion, biological concentration or its combination.
5. according to the described medicine of claim 4, it is characterized in that described certain dosage form is capsule or tablet, also comprises the container that is used to place described capsule or tablet, described container can be box, bottle, sack.
6. according to the described medicine of claim 4, it is characterized in that described certain dosage form is a solution, also comprises the container that is used to place described solution, described container can be a bottle.
7. according to the described medicine of claim 4, it is characterized in that, in described chemical compound specific markers position
13The C abundance is 60-90%.
8. according to the described medicine of claim 4, it is characterized in that, in described chemical compound specific markers position
13The C abundance is 60-85%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021346232A CN100402093C (en) | 2002-08-26 | 2002-08-26 | Medicine used in medical breath diagnosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021346232A CN100402093C (en) | 2002-08-26 | 2002-08-26 | Medicine used in medical breath diagnosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1478551A true CN1478551A (en) | 2004-03-03 |
| CN100402093C CN100402093C (en) | 2008-07-16 |
Family
ID=34145886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021346232A Expired - Fee Related CN100402093C (en) | 2002-08-26 | 2002-08-26 | Medicine used in medical breath diagnosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100402093C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101881763A (en) * | 2009-10-27 | 2010-11-10 | 天津赛德生物制药有限公司 | Urea breath detection kit for detecting stomach helicobacter pylori |
| CN104737016A (en) * | 2012-08-20 | 2015-06-24 | 大塚制药株式会社 | Method for measuring carbohydrate metabolism ability, and composition for use in said method |
| CN107115113A (en) * | 2008-07-29 | 2017-09-01 | 艾伦斯生物科技有限公司 | Breath test device and method |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3825098B2 (en) * | 1996-09-25 | 2006-09-20 | 東京瓦斯株式会社 | Diabetes diagnostic agent |
| CN1249036A (en) * | 1997-03-11 | 2000-03-29 | 菲舍尔分析仪器有限公司 | Carbon isotope analyser |
| AU9182698A (en) * | 1997-09-11 | 1999-03-29 | Oridion Medical Ltd. | Breath test analyser |
| WO1999056790A2 (en) * | 1998-05-06 | 1999-11-11 | Isotechnika, Inc. | 13c glucose breath test for the diagnosis of diabetes |
-
2002
- 2002-08-26 CN CNB021346232A patent/CN100402093C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107115113A (en) * | 2008-07-29 | 2017-09-01 | 艾伦斯生物科技有限公司 | Breath test device and method |
| CN107115113B (en) * | 2008-07-29 | 2021-02-12 | 艾伦斯生物科技有限公司 | Breath testing apparatus and method |
| CN101881763A (en) * | 2009-10-27 | 2010-11-10 | 天津赛德生物制药有限公司 | Urea breath detection kit for detecting stomach helicobacter pylori |
| CN104737016A (en) * | 2012-08-20 | 2015-06-24 | 大塚制药株式会社 | Method for measuring carbohydrate metabolism ability, and composition for use in said method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100402093C (en) | 2008-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Evans et al. | A bioorthogonal 68 Ga-labelling strategy for rapid in vivo imaging | |
| KR101635186B1 (en) | Active small-molecule donkey-hide gelatin mixture and preparation method and application thereof | |
| Tattersall et al. | Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease | |
| Cummings et al. | In vivo studies of amylose-and ethylcellulose-coated [13C] glucose microspheres as a model for drug delivery to the colon | |
| US20070166227A1 (en) | Crowned dithiocarbamate metal complexes and methods for their use | |
| Greenhill et al. | Prolactin, growth hormone and growth responses in boys with attention deficit disorder and hyperactivity treated with methylphenidate | |
| CN100402093C (en) | Medicine used in medical breath diagnosis | |
| CN101003540A (en) | Anti infectious compound and usage | |
| CN106474495B (en) | Imido- oxalic acid99mThe rgd peptide cancer diagnosis drug and preparation method thereof of Tc label | |
| CN108690129A (en) | A kind of hemp antigen and preparation method | |
| CN111233810B (en) | Preparation method and application of hydroxycinnamoyl ester type catechin | |
| Kronauge et al. | Synthesis and identification of the monocation Tc (CPI) 6+ in Tc (CNC (CH3) 2COOCH3) 6Cl and its hydrolysis products | |
| CN108982862A (en) | It is a kind of for detecting the immuno-chromatographic test paper strip and preparation method thereof of capsaicine in gutter oil | |
| CN104758269A (en) | Acetylcysteine effervescent tablet | |
| CN101724008A (en) | Marsdenia tenacissima C21 steroidal glycoside converted product and preparation method and application thereof | |
| CN104906068A (en) | Method for preparing low-hygroscopicity polymer composite capsule | |
| CN101891791B (en) | Derivate for labeling bile acid and reference compound, preparation method and application thereof | |
| CN109157527A (en) | A kind of Irbesartan Capsules and preparation method thereof | |
| CN113773283B (en) | Oxidobicycloheptene sulfonamide compound containing hydrophobic label and application thereof | |
| CN112390760B (en) | FAK-targeting compound and preparation method and application thereof | |
| CN112138175A (en) | A radionuclide99mPreparation method of Tc-labeled FAPI (FAPI) | |
| CN107674098B (en) | Aryl-containing boronic acids99mTc complex, its medicine box formula and application | |
| CN101003543A (en) | Anti infectious compound and usage | |
| Sternberg | Dual diagnosis: Addiction and affective disorders. | |
| CN101089020B (en) | VIP analog and its radioactive marker and their preparation process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHENZHEN CITY XIANYA BIOLOGICAL SCIENCE CO., LTD. Free format text: FORMER OWNER: MA YONGJIAN Effective date: 20090814 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20090814 Address after: Guangdong city of Shenzhen province Nanshan District Nanxin East Road and Taoyuan North Road Xiamen 15A1 SOHO Patentee after: Zhang Houde Address before: Room 16, building 302, Liwan garden, Nanshan District, Shenzhen, Guangdong Patentee before: Ma Yongjian |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080716 Termination date: 20200826 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |